We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of
Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

6032 Background: Platinum-based chemotherapy with cetuximab is the standard of care for
relapsed or metastatic squamous cell carcinoma of the head and neck (SCCHN). The aim of …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Head and neck squamous cell carcinomas (SCCHN) resulted in approximately 890,000 new
cases and 450,000 deaths in 2018, worldwide, representing the seventh most common …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …

Objective. To review the current state of the data on the use of cetuximab in head and neck
squamous cell carcinoma (HNSCC). Data Sources. The National Center for Biotechnology …